Overall, this study demonstrates that YAvns possess significant anti-proliferative activity against colon cancer cells, and may exert superior anti-migratory and anti-EMT activities as compared to major natural Avns, including the ability to modulate transcriptional factors involved in E-cadherin downregulation and EMT progression, suggesting enhanced functional properties as bioactive nutraceuticals. The gene discussed is CDH1; the disease is colonic neoplasm.